Welcome to our dedicated page for Kraig Biocraft Laboratories In news (Ticker: KBLB), a resource for investors and traders seeking the latest updates and insights on Kraig Biocraft Laboratories In stock.
Kraig Biocraft Laboratories (KBLB) pioneers advanced biomaterials through genetic engineering of recombinant spider silk. This dedicated news hub provides investors and industry stakeholders with essential updates on the company's scientific progress and strategic initiatives.
Access timely announcements covering production milestones, research breakthroughs, and partnership developments. Our curated collection includes press releases on genetic enhancements, scalable manufacturing achievements, and applications in technical textiles, medical devices, and defense materials.
Discover updates on proprietary silk protein innovations, including hybrid fibers combining spider and caddisfly DNA sequences. Track progress in commercializing sustainable alternatives to conventional materials through verified operational expansions and quality control advancements.
Bookmark this page for streamlined access to KBLB's official communications. Regularly updated content ensures informed decision-making about this biotechnology innovator's role in transforming material science markets.
Kraig Biocraft Laboratories (OTCQB: KBLB) has completed its spring spider silk production trials and is set to expand production in 2024. The company identified five key input parameters—nutrition, climate, genetic, staffing, and rearing conditions—that improved silkworm genetics and production processes, resulting in the largest and strongest silkworms and cocoons to date. Under the guidance of Dr. Nirmal Kumar, the team achieved significant advancements and is now accelerating the launch of larger-scale operations, starting nearly a month ahead of schedule with the next generation of BAM-1 spider silk hybrids.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced significant milestones, particularly the success of its spring production trials for spider silk. The company has heightened its investor communications and reviewed its investor relations (IR) program at the request of OTC Markets Group, ensuring all publications are compliant and factual. A recent editorial by 24/7 Market News highlighted advancements in spider silk, which the company verified as truthful. Kraig Labs has directed Hansel Capital and Karolus Maximus Kapital to provide shareholder updates, emphasizing a commitment to compliance and transparency. The company reported no insider trading or issuance of common stock in the past 90 days, except for the CEO acquiring one restricted share. Kraig Biocraft is focused on scaling production and maintaining high reporting standards.
Kraig Biocraft Laboratories, Inc. announces plans to expand production base into Cambodia to support the growth of its recombinant spider silk production. The Company's successful spring production trials have paved the way for rapid expansion and diversification of operations. With a target of one metric ton production before year's end, the Company aims to capitalize on its recent successes and continue scaling up its operations.
Kraig Biocraft Laboratories, Inc. (KBLB) announces successful spring production trials of its BAM-1 hybrid parental strains, exceeding expectations for scale, performance, and robustness. The trials demonstrated the readiness for rapid production expansion, marking the most successful cycle in the company's history. The parent strains showed strength and resilience, with no instances of disease. The company is now moving towards scaling production to metric ton levels.
Kraig Biocraft Laboratories, Inc. announces successful spring production trials for their BAM-1 hybrid parental strains, exceeding all expectations for scale, performance, and robustness. The trials demonstrated that the Company's BAM-1 recombinant spider silk hybrids are ready for rapid production expansion. Renowned expert Dr. Nirmal Kumar oversaw the production, resulting in the strongest and most resilient silkworm lines developed by Kraig Labs. The Company is now prepared to scale production to metric ton levels, targeting multiple production locations in multiple countries.
Kraig Biocraft Laboratories, Inc. reports signing landmark agreements with the Lam Dong Agro-Forestry Research Experiment Center in Vietnam for rearing and breeding specialized silkworms. The agreements outline a collaborative effort to integrate the Company's silk technologies, with the LAREC providing insights and assistance in selective breeding of the BAM-1 parental strains for local conditions. This strengthens the collaboration between Kraig Labs and governmental agencies in South East Asia, expanding the Company's operations.
FAQ
What is the current stock price of Kraig Biocraft Laboratories In (KBLB)?
What is the market cap of Kraig Biocraft Laboratories In (KBLB)?
